Skip to Content

Virtus LifeSci Biotech Products ETF BBP

Medalist Rating as of | See Virtus Investment Hub

Morningstar’s Analysis BBP

Will BBP outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Weakness in Virtus LifeSci Biotech Products ETF's People and Process Pillar ratings limits this strategy to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The strategy charges fees in line with its similarly distributed peers, priced within the middle quintile.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings BBP

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 19.7
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Mirum Pharmaceuticals Inc

2.23 498,327
Healthcare

Alnylam Pharmaceuticals Inc

2.19 489,557
Healthcare

Kiniksa Pharmaceuticals International PLC Class A

2.03 454,876
Healthcare

Legend Biotech Corp ADR

1.99 446,034
Healthcare

Travere Therapeutics Inc Ordinary Shares

1.99 444,437
Healthcare

Ligand Pharmaceuticals Inc

1.92 429,234
Healthcare

Lexicon Pharmaceuticals Inc

1.87 419,335
Healthcare

Ionis Pharmaceuticals Inc

1.86 415,347
Healthcare

ACADIA Pharmaceuticals Inc

1.81 404,872
Healthcare

Day One Biopharmaceuticals Inc

1.81 404,797
Healthcare